Key Highlights
- Second-quarter net product revenues were about $208,000, up about 106% from about $101,000 a year earlier.
- Operating expenses rose to about $2.33 million, and the net loss was about $2.40 million, or about $0.90 per share.
- The company explicitly stated there is substantial doubt about its ability to continue as a going concern.
- It reported reaching minimum enrollment in a hospitalized-babesiosis study, with interim data expected around October 2026.
60 Degrees Pharmaceuticals (NASDAQ:SXTP), trading as a Penny Stock at $1.03, fell 2.83% at last closing. The small specialty pharmaceutical company focused on infectious and vector-borne diseases grew its modest product Revenue in the second quarter but operates with heavy losses, minimal revenue, substantial dilution and an explicit going-concern warning. For investors, the question of whether the pullback is a warning or a contrarian setup must be weighed against the company's precarious finances.
60 Degrees Pharmaceuticals markets ARAKODA, an FDA-approved drug for malaria prevention, and is advancing Clinical Trials of tafenoquine for babesiosis, a tick-borne illness. Its value depends above all on its ability to fund its operations as a micro-cap, deeply lossmaking company.
Latest Developments
In its second-quarter 2026 results, 60 Degrees reported net product revenues of about $208,000, up about 106% from about $101,000 a year earlier, with Gross Profit of about $57,000, while operating expenses rose to about $2.33 million and its net loss was about $2.40 million, about $0.90 per share. The company explicitly stated that there is substantial doubt about its ability to continue as a going concern, and it has raised Capital through dilutive offerings. On the clinical side, it reported reaching minimum enrollment in a hospitalized-babesiosis study, with interim data expected around October 2026.
Financial and Business Position
The modest revenue growth is dwarfed by the company's losses, and its financial position dominates the picture: minimal revenue, operating expenses and a net loss many times larger, substantial Shareholder dilution, and an explicit going-concern warning. Its FDA-approved ARAKODA and its babesiosis clinical program offer potential, but the company's ability to fund itself is the central and pressing risk.
Stock-Market Context
60 Degrees Pharmaceuticals (NASDAQ:SXTP) fell 2.83% at last closing, consistent with the highly speculative profile of a micro-cap company facing a going-concern warning. Any contrarian case would rest on the babesiosis program delivering positive data and ARAKODA sales accelerating, alongside the company securing financing; the cautionary case is substantial, including the minimal revenue and the going-concern uncertainty.
What Investors Should Watch
Investors may focus on the babesiosis clinical program, including the interim data, ARAKODA sales, and the cash position and any financing. Given the financial distress and going-concern uncertainty, the company's ability to fund itself and advance its programs would determine whether the weakness is an opportunity or a warning.






Please wait processing your request...